PubRank

Michael Brundage

Author PubWeight™ 38.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011 5.76
2 Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol 2014 2.25
3 Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005 2.06
4 ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res 2013 1.96
5 Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005 1.80
6 Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 2008 1.69
7 Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys 2002 1.66
8 Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). Int J Radiat Oncol Biol Phys 2008 1.52
9 Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 2007 1.27
10 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 2006 1.26
11 The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer 2008 1.07
12 The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes 2013 1.02
13 The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis. Radiother Oncol 2013 1.01
14 A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 2013 1.01
15 Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev Pharmacoecon Outcomes Res 2010 1.00
16 Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J 2012 0.99
17 Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. BJU Int 2006 0.94
18 Development of indicators of the quality of radiotherapy for localized prostate cancer. Radiother Oncol 2011 0.93
19 Managing a national radiation oncologist workforce: a workforce planning model. Radiother Oncol 2012 0.91
20 Orbital metastasis secondary to merkel cell carcinoma: case report and literature review. Orbit 2013 0.86
21 Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. Eur J Cancer 2009 0.86
22 Integrating patient-reported outcomes in healthcare policy, research and practice. Expert Rev Pharmacoecon Outcomes Res 2010 0.85
23 Reporting quality of life in clinical trials: a CONSORT extension. Lancet 2011 0.85
24 Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. Value Health 2007 0.84
25 Information priorities of Italian early-stage prostate cancer patients and of their health-care professionals. Patient Educ Couns 2005 0.81
26 Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. BJU Int 2012 0.80
27 The prostate cancer risk stratification project: database construction and risk stratification outcome analysis. J Natl Compr Canc Netw 2014 0.80
28 Information needs of post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy. Patient Educ Couns 2013 0.78
29 Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline. Can J Urol 2002 0.77
30 Information for decision making by post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy. Breast 2013 0.77
31 Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer. Can Urol Assoc J 2013 0.76